Silk Road Medical (NASDAQ:SILK) Reaches New 12-Month High at $54.06

Silk Road Medical, Inc (NASDAQ:SILKGet Rating) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $54.06 and last traded at $53.52, with a volume of 11210 shares traded. The stock had previously closed at $50.90.

Analyst Upgrades and Downgrades

SILK has been the subject of several recent analyst reports. Citigroup lifted their price target on Silk Road Medical to $38.00 in a research report on Tuesday, November 15th. Bank of America began coverage on Silk Road Medical in a report on Tuesday. They issued a “buy” rating and a $60.00 price objective for the company.

Silk Road Medical Stock Up 2.3 %

The stock has a 50 day simple moving average of $45.18 and a 200-day simple moving average of $41.05. The company has a debt-to-equity ratio of 1.30, a quick ratio of 5.29 and a current ratio of 6.14.

Insider Buying and Selling at Silk Road Medical

In other Silk Road Medical news, CFO Lucas W. Buchanan sold 24,800 shares of the business’s stock in a transaction dated Friday, November 11th. The stock was sold at an average price of $50.00, for a total transaction of $1,240,000.00. Following the completion of the sale, the chief financial officer now directly owns 176,527 shares in the company, valued at approximately $8,826,350. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Erica J. Rogers sold 10,000 shares of Silk Road Medical stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $43.62, for a total transaction of $436,200.00. Following the transaction, the chief executive officer now directly owns 246,199 shares of the company’s stock, valued at approximately $10,739,200.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Lucas W. Buchanan sold 24,800 shares of Silk Road Medical stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $50.00, for a total value of $1,240,000.00. Following the transaction, the chief financial officer now directly owns 176,527 shares in the company, valued at $8,826,350. The disclosure for this sale can be found here. Insiders sold a total of 73,506 shares of company stock worth $3,422,494 in the last three months. 7.66% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. M&T Bank Corp lifted its holdings in Silk Road Medical by 4.0% in the 3rd quarter. M&T Bank Corp now owns 74,679 shares of the company’s stock worth $3,361,000 after purchasing an additional 2,890 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Silk Road Medical by 4.3% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,404,788 shares of the company’s stock worth $63,216,000 after purchasing an additional 57,544 shares in the last quarter. Balyasny Asset Management LLC purchased a new position in Silk Road Medical in the 3rd quarter worth approximately $7,096,000. BNP Paribas Arbitrage SNC lifted its holdings in Silk Road Medical by 170.1% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 20,871 shares of the company’s stock worth $939,000 after purchasing an additional 13,144 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in Silk Road Medical by 5.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 403,177 shares of the company’s stock worth $18,143,000 after purchasing an additional 21,521 shares in the last quarter.

Silk Road Medical Company Profile

(Get Rating)

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Featured Stories

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.